contact

Dr. Aurelius Omlin

titel Dr. med.

first name Aurelius

last name Omlin

street Rorschacherstrasse 95

city 9007 St.Gallen

country Switzerland

phone number 071 494 11 11

fax 071 494 63 25

e-mail aurelius.omlin@kssg.ch

2

publications

title

journalpaper/review

Gillessen Sommer S, Omlin A, Attard G, de Bono J S, Efstathiou E, FizaziK, Halabi S, Nelson P S, Sartor O, Smith M R, Soule H R, Akaza H, Beer TM, Beltran H, Chinnaiyan A M, Daugaard G, Davis I D, De Santis M, DrakeC G, Eeles R A, Fanti S, Gleave M E, Heidenreich A, Hussain M, James ND, Lecouvet F E, Logothetis C J, Mastris K, Nilsson S, Oh W K, Olmos D,Padhani A R, Parker C, Rubin M A, Schalken J A, Scher H I, Sella A, ShoreN D, Small E J, Sternberg C N, Suzuki H, Sweeney C J, Tannock I F,Tombal B. Management of patients with advanced prostate cancer:recommendations of the St Gallen Advanced Prostate Cancer ConsensusConference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.

Desax M C, Hundsberger T, Rothermundt C, Omlin A, Gillessen SommerS. Restless Legs Syndrome—An Emerging Potential Side Effect ofEnzalutamide: Report of 2 Cases. Clin Genitourin Cancer 2015; 13:e385-6.

Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono J S, Shen L, SuZ, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, NailChanges, Peripheral Neuropathy, and Dysgeusia in Prostate CancerPatients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer2015;.

Schmid S, Omlin A, Blum D, Strasser F, Gillessen Sommer S,Rothermundt C. Assessment of Anticancer-Treatment Outcome in Patientswith Metastatic Castration-Resistant Prostate Cancer - Going beyond PSAand Imaging, a Systematic Literature Review. Ann Oncol 2015;.

Gillessen Sommer S, Fanti S, Omlin A, panelists and authors of APCCC .Reply to the letter to the editor 'Management of patients with advancedprostate cancer: recommendations of the St Gallen Advanced ProstateCancer Consensus Conference (APCCC) 2015' by Gillessen et al. AnnOncol 2015; 26:2354-5.

3

publications

title

journalpaper/review

Blum D, Koeberle D, Omlin A, Walker J, von Moos R, Mingrone W, deWolf-Linder S, Hayoz S, Kaasa S, Strasser F, Ribi K. Feasibility and acceptanceof electronic monitoring of symptoms and syndromes using a handheldcomputer in patients with advanced cancer in daily oncology practice.Support Care Cancer 2014; 22:2425-34.

Omlin A, Stienen M N, Brügge D, Fretz C, Gillessen Sommer S,Hundsberger T. Maligne spinale Kompression: Prävention, Erkennungund «State of the Art»-Behandlung. SMF 2014; 14:820-825.

Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, AltavillaA, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen Sommer S, deBono J, Attard G. Tumour responses following a steroid switch fromprednisone to dexamethasone in castration-resistant prostate cancerpatients progressing on abiraterone. Br J Cancer 2014;.

Hundsberger T, Omlin A, Haegele-Link S, Vehoff J, Strasser F. AutonomicDysfunction in Cancer Cachexia Coincides With Large FiberPolyneuropathy. J Pain Symptom Manage 2014; 48:611-618.

Molife L R, Omlin A, Jones R J, Karavasilis V, Bloomfield D, Lumsden G,Fong P C, Olmos D, O'Sullivan J M, Pedley I, Hickish T, Jenkins P,Thompson E, Oommen N, Wheatley D, Heath C, Temple G, Pelling K, deBono J S. Randomized Phase II trial of nintedanib, afatinib and sequentialcombination in castration-resistant prostate cancer. Future Oncol 2014;10:219-31.

Templeton A, Pezaro C, Omlin A, McNamara M G, Leibowitz-Amit R, Vera-Badillo F E, Attard G, de Bono J S, Tannock I F, Amir E. Simple prognosticscore for metastatic castration-resistant prostate cancer withincorporation of neutrophil-to-lymphocyte ratio. Cancer 2014;120:3346-52.

4

publications

title

journalpaper/review

Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of noveltherapeutics in advanced prostate cancer following docetaxelchemotherapy. Ther Adv Urol 2014; 6:3-14.

Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N J,Gillessen Sommer S. Abiraterone--what is wrong with the adrenalglands?. Clin Genitourin Cancer 2014; 12:e133-7.

Pezaro C, Omlin A, Perez-Lopez R, Mukherji D, Attard G, Bianchini D,Lorente D, Parker C, Dearnaley D, de Bono J S, Sohaib A, Tunariu N.Progressive computed tomography (CT) appearances precedingmalignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin Radiol 2014;.

Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, FerraldeschiR, Zivi A, Attard G, Chowdhury S, de Bono J S. Reply to: Enzalutamideafter failure of docetaxel and abiraterone in metastatic castrate resistantprostate cancer. Eur J Cancer 2014; 50:1042-3.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S,Prandi D, Lorente D, Frenel J S, Pezaro C, Omlin A, Rodrigues D N, FlohrP, Tunariu N, S de Bono J, Demichelis F, Attard G. Tumor clone dynamicsin lethal prostate cancer. Sci Transl Med 2014; 6:254ra125.

Blagden S, Omlin A, Omlin A, Josephs D, Stavraka C, Zivi A, Pinato D J,Anthoney A, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K,Shiokawa R, Inatani M, Prince J, Jones K, Twelves C, Spicer J, Banerji U.First-in-human study of CH5132799, an oral class I PI3K inhibitor,studying toxicity, pharmacokinetics, and pharmacodynamics, in patientswith metastatic cancer. Clin Cancer Res 2014; 20:5908-17.

5

publications

title

journalpaper/review

Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastaticcastration-resistant prostate cancer (CRPC): preclinical and clinicalevidence for the sequential use of novel therapeutics. Cancer MetastasisRev 2014; 33:555-66.

Weisshaupt C, Hitz F, Albrich W C, Omlin A. Pulmonary actinomycosis andHodgkin's disease: when FDG-PET may be misleading. BMJ Case Rep2014; 2014:.

Leibowitz-Amit R, Templeton A, Omlin A, Pezaro C, Atenafu E G, KeizmanD, Vera-Badillo F, Seah J A, Attard G, Knox J J, Sridhar S S, Tannock I F,de Bono J S, Joshua A M. Clinical variables associated with PSA responseto abiraterone acetate in patients with metastatic castration-resistantprostate cancer. Ann Oncol 2014; 25:657-62.

Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I,Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J,Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R,Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. PTENProtein Loss and Clinical Outcome from Castration-resistant ProstateCancer Treated with Abiraterone Acetate. Eur Urol 2014;.

Yap T A, Lorente D, Omlin A, Olmos D, de Bono J S. Circulating tumorcells: a multifunctional biomarker. Clin Cancer Res 2014; 20:2553-68.

Loriot Y, Fizazi K, Jones R J, Van den Brande J, Molife R L, Omlin A, JamesN D, Baskin-Bey E, Heeringa M, Baron B, Holtkamp G M, Ouatas T, deBono J S. Safety, tolerability and anti-tumour activity of the androgenbiosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest NewDrugs 2014; 32:995-1004.

6

publications

title

journalpaper/review

Sandhu S K, Omlin A, Hylands L, Miranda S, Barber L J, Riisnaes R, ReidA H, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, FenwickK, Assiotis I, Olmos D, Yap T A, Fong P, Tunariu N, Koh D, Molife L R,Kaye S, Lord C J, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase(PARP) inhibitors for the treatment of advanced germline BRCA2 mutantprostate cancer. Ann Oncol 2013; 24:1416-8.

Yap T A, Omlin A, de Bono J S. Development of therapeutic combinationstargeting major cancer signaling pathways. J Clin Oncol 2013;31:1592-605.

Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D,Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, deBono J. Improved survival in a cohort of trial participants with metastaticcastration-resistant prostate cancer demonstrates the need for updatedprognostic nomograms. Eur Urol 2013; 64:300-6.

Pezaro C, Mukherji D, Tunariu N, Cassidy A M, Omlin A, Bianchini D, SeedG, Reid A H M, Olmos D, de Bono J S, Attard G. Sarcopenia and change inbody composition following maximal androgen suppression withabiraterone in men with castration-resistant prostate cancer. Br J Cancer2013; 109:325-31.

Pezaro C J, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R,Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, deBono J S, Attard G. Visceral Disease in Castration-resistant ProstateCancer. Eur Urol 2013; 65:270-3.

Laurent J, Touvrey C, Gillessen Sommer S, Joffraud M, Vicari M, BertrandC, Ongarello S, Liedert B, Gallerani E, Beck J, Omlin A, Sessa C,Quaratino S, Stupp R, Gnad-Vogt U S, Speiser D E. T-cell activation bytreatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.

7

publications

title

journalpaper/review

Sandhu S K, Schelman W R, Wilding G, Moreno V, Baird R D, Miranda S,Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K,Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye S B, de Bono J S, Wenham R M. The poly(ADP-ribose)polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers andpatients with sporadic cancer: a phase 1 dose-escalation trial. LancetOncol 2013; 14:882-92.

Omlin A, Blum D, Wierecky J, Haile S, Ottery F D, Strasser F. Nutritionimpact symptoms in advanced cancer patients: frequency and specificinterventions, a case-control study. J Cachexia Sarcopenia Muscle 2013;4:55-61.

Pezaro C J, Omlin A, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D,Dearnaley D, Parker C, de Bono J S, Attard G. Activity of Cabazitaxel inCastration-resistant Prostate Cancer Progressing After Docetaxel andNext-generation Endocrine Agents. Eur Urol 2013;.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, FerraldeschiR, Zivi A, Attard G, Chowdhury S, de Bono J S. Antitumour activity ofenzalutamide (MDV3100) in patients with metastatic castration-resistantprostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur JCancer 2013; 50:78-84.

Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D,Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A,Rathkopf D E, Attard G, Scher H I, de Bono J, Danila D C. First-in-humanPhase I study of EZN-4176, a locked nucleic acid antisenseoligonucleotide to exon 4 of the androgen receptor mRNA in patients withcastration-resistant prostate cancer. Br J Cancer 2013; 109:2579-86.

8

publications

title

journalpaper/review

Renz M, Mao S M, Omlin A, Büche D, Cerny T, Strasser F. SpiritualExperiences of Transcendence in Patients With Advanced Cancer. Am JHosp Palliat Care 2013;.

Omlin A, Pezaro C J, Zaidi S, Lorente D, Mukherji D, Bianchini D,Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono J S,Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone anddiethylstilboestrol when administered sequentially to men withcastration-resistant prostate cancer'. Br J Cancer 2013; 110:267-8.

Omlin A, Pezaro C J, Zaidi S, Lorente D, Mukherji D, Bianchini D,Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono J S,Attard G. Antitumour activity of abiraterone and diethylstilboestrol whenadministered sequentially to men with castration-resistant prostatecancer. Br J Cancer 2013; 109:1079-84.

Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients withcastration-resistant disease. Hematol Oncol Clin North Am 2013;27:1243-60, ix.

Omlin A, Gillessen Sommer S. [Inhibitors of androgen and estrogenbiosynthesis in castration-resistant prostate cancer]. Urologe A 2012;51:8-14.

Omlin A, de Bono J S. Therapeutic options for advanced prostate cancer:2011 update. Curr Urol Rep 2012; 13:170-8.

Blum D, Omlin A, Baracos V E, Solheim T S, Tan B H L, Stone P, Kaasa S,Fearon K, Strasser F, European Palliative Care Research Collaborative .Cancer cachexia: a systematic literature review of items and domainsassociated with involuntary weight loss in cancer. Crit Rev Oncol Hematol2011; 80:114-44.

9

publications

title

journalpaper/review

Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogeniccoating of long-term venous catheter for cancer patients: a prospective,randomised, double-blind trial. Ann Hematol 2011; 91:613-20.

Yap T A, Zivi A, Omlin A, de Bono J S. The changing therapeuticlandscape of castration-resistant prostate cancer. Nat Rev Clin Oncol2011; 8:597-610.

Joerger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advancednon small-cell lung cancer: special focus on pharmacology andmechanism of action. Current drug targets 2010; 11:37-47.

Omlin A, Kälin M, Templeton A, Gillessen Sommer S, Graf H J,Rothermundt C. Metastasiertes Prostatakarzinom –Behandlungsmöglichkeiten nach der Hormontherapie. Swiss MedicalForum 2010; 10:483-485.

Blum D, Omlin A, Fearon K, Baracos V, Radbruch L, Kaasa S, Strasser F,European Palliative Care Research Collaborative . Evolving classificationsystems for cancer cachexia: ready for clinical practice?. Support CareCancer 2010; 18:273-9.

Rothermundt C, Omlin A, Gillessen Sommer S. 'Sunitinib withdrawalphenomenon' or spontaneous regression in renal cell cancer. Annals ofoncology : official journal of the European Society for Medical Oncology /ESMO 2009; 20:1144-6.

Omlin A, Strasser F. Gewichts- und Appetitverlust bei Krebspatienten. TheMedical Journal 2009 2009; 3:27-29.

Omlin A, D'Addario G, Gillessen Sommer S, Cerny T, Früh M. Activity ofpemetrexed against brain metastases in a patient with adenocarcinomaof the lung. Lung cancer (Amsterdam, Netherlands) 2009; 65:383-4.

10

publications

title

journalpaper/review

Spirig C, Omlin A, D'Addario G, Loske K D, Geismar J H, Ruhstaller T.Radiation recall dermatitis with soft tissue necrosis following pemetrexedtherapy: a case report. J Med Case Reports 2009; 3:93.

Templeton A, Omlin A, Strasser F. An update on the pharmacologicalmanagement of the cancer anorexia-cachexia-syndrome. EuropeanJournal of Palliative Care 2007; 14:186-190.

Omlin A, Amichetti M, Azria D, Cole B F, Fourneret P, Poortmans P,Naehrig D, Miller R C, Krengli M, Gutierrez Miguelez C, Morgan D,Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D,Oppitz U, Abacioglu U, Gruber G. Boost radiotherapy in young womenwith ductal carcinoma in situ: a multicentre, retrospective study of theRare Cancer Network. The lancet oncology 2006; 7:652-6.

Omlin A, Mühlemann K, Fey M F, Pabst T. Pneumococcal vaccination insplenectomised cancer patients. European journal of cancer (Oxford,England : 1990) 2005; 41:1731-4.

11

projects

title status

Phase II Trial of Pembrolizumab (MK-3475) in Subjects withMetastatic Castration-Resistant Prostate Cancer (mCRPC)Previously Treated with Chemotherapy (KEYNOTE-199) /MK-3475-199 Pembro Prostata

ongoing- followup

Single arm open label phase II pilot study of carboplatin inpatients with metastatic castration-resistant prostate cancer(CRPC) and PTEN-loss and/or DNA repair defects. PRO-PLAT

ongoing- followup

12

projects

title status

An Open Label Biomarker Driven Phase II Clinical Trial ofAbiraterone Acetate (AA) Re-Challenge in Patients withMetastatic Castration-Resistant Prostate Cancer and PriorResponse to AA (Abi-RE)

ongoing- followup

An open-label, multicohort, phase II study of MPDL3280A inadvanced solid tumors

ongoing- followup

13

projects

title status

A phase III, open-label, multicenter, randomized study toinvestigate the efficacy and safety of MPDL3280A (ANTI−PD-L1ANTIBODY) compared with chemotherapy in patients withlocally advanced or metastatic urothelial bladder cancer afterfailure with platinum-containing chem-otherapy. GO29294

ongoing- followup

MP0250; A phase I multi-centre, open-label, repeated-dose,dose-escalation study to assess safety, tolerability andpharmacokinetics of MP0250 in patients with advanced solidtumours

automat-icallyclosed

SINGLE ARM OPEN LABLE PHASE II PILOT STUDY OFCARBOPLATIN

scheduled

SAKK 63/12 Prospective cohort study with collection of clinicaldata and serum of patients with prostate disease

ongoing- followup

14

projects

title status

Prevention of symptomatic skeletal events with denosumabadministered every 4 weeks versus every 12 weeks: Anoninferiority phase III trial (SAKK 96/12, REDUSE)

ongoing- followup

Swiss Austrian German Testicular Cancer Cohort Study – SAGTCCS

ongoing- followup

LDE225 in combination with Paclitaxel in patients withadvanced solid tumors. A multicenter phase I trial

automat-icallyclosed

Entwicklung von Dienstleistungsmodellen der integriertenOnkologie und Palliative Care: Untersuchung von temporalenAspekten, Involvierung von Onkologen, und Chemotherapie-Gebrauch

completed

The European Palliative Care Research Collaborative. Improvedtreatment of pain, depression and fatigue through translationresearch

completed